INVO Bioscience Files 8-K on Jan 19 Event; Nasdaq Listing Confirmed

TL;DR

**INVO Bioscience filed a routine 8-K, no new material info for traders.**

AI Summary

INVO Bioscience, Inc. filed an 8-K on February 1, 2024, reporting an "Other Event" that occurred on January 19, 2024. This filing primarily serves to update administrative information, confirming the company's registration on The Nasdaq Stock Market LLC under the trading symbol "INVO" for its Common Stock, $0.0001 par value. For investors, this filing is a routine administrative update and does not signal any immediate operational or financial changes, meaning it's unlikely to directly impact stock value.

Why It Matters

This filing is largely administrative, confirming INVO Bioscience's listing on Nasdaq, which is already known to investors. It doesn't contain new financial or operational news that would typically move the stock.

Risk Assessment

Risk Level: low — The filing is administrative and does not disclose any new risks or significant events that would impact the company's operations or financial standing.

Analyst Insight

A smart investor would recognize this as a routine administrative filing and not expect any immediate stock price movement. It's a non-event for trading decisions.

Key Numbers

• $0.0001 — Common Stock Par Value (This is the stated par value of INVO Bioscience's common stock.)

Key Players & Entities

• INVO Bioscience, Inc. (company) — the registrant filing the 8-K
• The Nasdaq Stock Market LLC (company) — the exchange where INVO's stock is registered
• January 19, 2024 (date) — date of the earliest event reported
• February 1, 2024 (date) — date the 8-K was filed
• $0.0001 (dollar_amount) — par value of Common Stock

Forward-Looking Statements

• INVO Bioscience's stock price will remain stable following this filing. (INVO) — high confidence, target: 2024-02-08

FAQ

Key Financial Figures

• $0.0001 — ction 12(b) of the Act: Common Stock, $0.0001 par value INVO The Nasdaq Stock Mar
• $5.00 — Preferred Stock at a purchase price of $5.00 per share. The parties agreed that NAYA
• $500,000 — ad failed to fund the second tranche of $500,000 due no later than January 19, 2024. I

Filing Documents

• form8-k.htm (8-K) — 34KB
• 0001493152-24-004574.txt ( ) — 200KB
• invo-20240119.xsd (EX-101.SCH) — 3KB
• invo-20240119_lab.xml (EX-101.LAB) — 33KB
• invo-20240119_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 3KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 19, 2024 INVO BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 001-39701 20-4036208 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 5582 Broadcast Court Sarasota , Florida 34240 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (978) 878-9505 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Common Stock, $0.0001 par value INVO The Nasdaq Stock Market LLC (Title of Each Class) (Trading Symbol) (Name of Each Exchange on Which Registered) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (CFR 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (CFR 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01 Other Events As previously disclosed in a Current Report on Form 8-K filed on January 3, 2024, INVO Bioscience, Inc., a Nevada corporation (the " Company ") entered into a securities purchase agreement (the " SPA ") with NAYA Bioscience, Inc. (" NAYA ") on December 29, 2023 for NAYA's purchase of 1,000,000 shares of the Company's Series A Preferred Stock at a purchase price of $5.00 per share. The parties agreed that NAYA's purchases will be made in tranches in accordance with the Minimum Interim Pipe Schedule. The SPA contains customary representations, warranties and covenants of the Company and NAYA. As of January 31, 2024, NAYA had failed to fund the second tranche of $500,000 due no later than January 19, 2024. In accordance with t he previously announced agreement and plan of merger (the " Merger Agreement ") by and among the Company, INVO Merger Sub, Inc. (" Merger Sub "), and NAYA, the Company is now seeking to secure alternative funding to make up for the shortfall. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 1, 2024 INVO BIOSCIENCE, INC. By: /s/ Steven Shum Steven Shum Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR